Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Fearing that drug resistant malaria will reach Africa, Prof François Nosten and his team are among those scientists who are scrambling to stop it while they still can. Drug resistance to artemisinin has been steadily increasing in Southeast Asia. Having emerged in Cambodia in 2007, it since has been recorded in Thailand, Vietnam and Myanmar. Artemisinin is the last remaining effective drug against the resistant falciparum strain, and there are no suitable replacements yet.

Mosquito
Load More

Similar stories

RECOVERY trial finds Regeneron’s monoclonal antibody combination reduces deaths for hospitalised COVID-19 patients who have not mounted their own immune response

The Randomised Evaluation of COVID-19 Therapy (RECOVERY) trial has demonstrated that the investigational antibody combination developed by Regeneron reduces the risk of death when given to patients hospitalised with severe COVID-19 who have not mounted a natural antibody response of their own.

RECOVERY trial finds aspirin does not improve survival for patients hospitalised with COVID-19

The RECOVERY trial was established as a randomised clinical trial to test a range of potential treatments for patients hospitalised with COVID-19. Patients with COVID-19 are at increased risk of blood clots forming in their blood vessels, particularly in the lungs. Between November 2020 and March 2021, the RECOVERY trial included nearly 15,000 patients hospitalised with COVID-19 in an assessment of the effects of aspirin, which is widely used to reduce blood clotting in other diseases. There was no significant difference in the primary endpoint of 28-day mortality

The COVID-19 International Modelling Consortium (CoMo Consortium) enters a new phase

Created in March 2020 to assist policymakers to make use of existing evidence in mathematical and epidemiological models to inform strategies for minimising the impact of COVID-19, the CoMo Consortium brings together mathematical modellers, epidemiologists, health economists and public health experts from more than 40 countries across Africa, Asia and South and North America.

ASM Editor in conversation with Nick White

Malaria continues to be a major killer, particularly in sub-Saharan Africa, affecting the world’s most vulnerable populations with more than 500,000 deaths per year, most of them African children. Emergence of resistance to antimalarial drugs is major public health issue. American Society for Microbiology Editor Dr Cesar Arias discusses with Professor Sir Nick White the latest information on this rapidly evolving field.

New Pandemic Sciences Centre at the University of Oxford

The University of Oxford announces the launch of a centre of global research collaboration and excellence, the Pandemic Sciences Centre. The need for partnership between academic excellence, industry and public health organisations is one of the key lessons learned from the coronavirus pandemic. This centre will unite disciplines, and sectors, to build agile, equitable partnerships that can tackle complex problems and respond to pandemic threats at any time.

AMR and scrub typhus among Chiangrai Unit's research priorities

Which infections are most common in the Chiangrai region? How should we treat them and how can we improve diagnostic? Which strategies are most effective in directing antibiotic treatment? Blog by Carlo Perrone, research physician based at the Chiang Rai Clinical Research Unit in Chiangrai, Thailand.